Esperion Therapeutics (ESPR) Equity Ratio (2012 - 2026)

Esperion Therapeutics has reported Equity Ratio for 15 years, with the latest figure at 0.67 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 49.39% year-over-year to 0.67; the trailing twelve-month figure through Mar 2026 stood at 0.67 (up 49.39% YoY), and the FY2025 full-year result was 0.65, up 42.67% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.67, down from 0.65 in the prior quarter.
• The five-year high for Equity Ratio was 0.65 in Q4 2025, with the low at 2.21 in Q4 2023.
• Historically, Equity Ratio has averaged 1.18 across 5 years, with a median of 1.18 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio sank 153.02% — and 2026, when it surged 49.39%.
• Esperion Therapeutics' Equity Ratio stood at 1.31 in 2022, then plunged by 69.3% to 2.21 in 2023, then surged by 48.86% to 1.13 in 2024, then soared by 42.67% to 0.65 in 2025, then declined by 2.72% to 0.67 in 2026.
• The last three Equity Ratio figures came in at 0.67 (Q1 2026), 0.65 (Q4 2025), and 1.24 (Q3 2025), per Business Quant data.